TAM Got Larger

Reason to Recalibrate

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

This is a follow-up piece to the original CYTK post published here.

Cytokinetics delivered solid data today and the headline is clean: ACACIA-HCM met both dual primary endpoints, with statistically significant improvements at Week 36 versus placebo in both KCCQ Clinical Summary Score and maximal exercise capacity (pVO2). The data behind the headline is worth sitting with.